That is, until last December, when the FDA approved “two milestone treatments,” Casgevy and Lyfgenia, the first gene therapies for the treatment of SCD in patients 12 years and older. Within months, ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. As 2025 begins, emerging biotechnology firms can ...

Bluebird bio is a case study. The company has three approved gene therapies: Zynteglo for beta thalassemia, Skysona for cerebral adrenoleukodystrophy and Lyfgenia for sickle cell. Yet the firm has ...

Srinivasa Reddy Mukkala also contributed to another life threatening new gene therapy submission: LYFGENIA for Sickle Cell Disease. This therapy, approved in December 2023, established his name in ...

Story continues below this ad 4. Casgevy and Lyfgenia: In December 2023, the FDA approved two groundbreaking treatments, Casgevy and Lyfgenia, the first cell-based gene therapies to treat sickle cell ...

The FDA is scrutinising reports of haematological cancers in patients treated with bluebird bio's Skysona gene therapy for neurological disease CALD The US FDA has cleared two novel gene therapies ...

In December 2023, it was announced that the US Food and Drug Administration had approved two breakthrough treatments. 3 Lyfgenia and Casgevy are the first gene therapies available for treating sickle ...

NEW YORK – The US Food and Drug Administration in 2024 approved dozens of new and expanded precision medicine indications. Although most of these approvals were still in cancer and rare conditions, ...